A Phase I clinical trial using DEX to treat advanced melanoma illustrated that Dex treatment enhanced the proportion and absolute number of circulating NK cells and restored the expression of a type II transmembrane receptor Natural Killer Group 2 member D (NKG2D), which is expressed on circulating T and NK cells [117], thus stimulating the MHC unrestricted NKG2D dependent cytotoxicity. The gene discussed is KLRK1; the disease is melanoma.